Literature DB >> 21368480

[Salvage surgery in esophageal cancer treatment -- its review in this decade and promises for the next decade].

Nobukazu Hokamura1.   

Abstract

Since admirable therapeutic results from definitive chemoradiotherapy(CRT)have been reported, it has been a curative option for all clinical stages of esophageal squamous cell carcinoma(ESCC)that could preserve the esophagus. From 2001 to 2009, we treated 981 new patients with ESCC in our institute. The rate of patients who chose definitive CRT as curative modality remained at about 70% in stage I and 20% in stage II - III . The number of salvage surgeries have not increased dramatically. In this decade, we had 97 cases of salvage surgery with right thoracotomy. Pathologically, no residual(R0) resection was performed in 80(82%)cases. The earlier the clinical stage, the better the overall survival. Seven patients(7%) died of severe complications, including bronchial necrosis and airway fistula. To avoid lethal complications, we established a retrosternal gastric pull-up without prophylactic neck lymph node dissection as a standard procedure of salvage surgery in 2006. Compared to other therapeutic treatments before and after 2006, this procedure could reduce fatal complications. However, overall survival remained at the same level. Salvage surgery is a complement to definitive CRT. It is necessary, therefore, to consider definitive CRT and salvage surgery comprehensively so as to increase positive therapeutic results with this multimodal strategy in patients with ESCC.

Entities:  

Mesh:

Year:  2011        PMID: 21368480

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies.

Authors:  Kazuki Sudo; Takashi Taketa; Arlene M Correa; Maria-Claudia Campagna; Roopma Wadhwa; Mariela A Blum; Ritsuko Komaki; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Heath D Skinner; Dipen M Maru; David C Rice; Stephen G Swisher; Wayne L Hofstetter; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.